Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. New Zealand
  4. New Zealand Stock Exchange
  5. TruScreen Group Limited
  6. News
  7. Summary
    TRU   NZTRUE0001S7


End-of-day quote. End-of-day quote New Zealand Stock Exchange - 07/23
0.065 NZD   -1.52%
07/08TRUSCREEN : Director Nominations Closing Date
07/01TRUSCREEN : First Sales Made in Eastern Europe
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

TruScreen : Research Confirms TruSreeen Suitability in COVID-19 Environment

03/24/2021 | 06:27am EDT

Cervical cancer screening company, TruScreen Group Limited (NZX and ASX:TRU) (Truscreen or Company), is pleased to report that its TruScreen cervical cancer screening device continues to gain recognition around the world.

The WHO strategy names the measurable global targets to prevent and treat cervical cancer: 90-70-90 by 2030: 90% of girls fully vaccinated with HPV vaccine by 15 years of age; 70% of women screened using a high‐performance test by age 35, and again by age 45; 90% of women identified with preinvasive and invasive cervical cancer effectively managed1. These ambitious goals require innovative technologies.

Covid-19 pandemic added further threat to health systems around the world: e.g., severe hospital capacity constraints, issues with infection control and the under-diagnosis of cancer.

Researchers in China explored the impact of using TruScreen cervical cancer screening device in the absence of colposcopy and PAP facilities and commented on the limitations of HPV testing and colposcopy under Covid-19 conditions2.

In a Covid-19 affected hospital and healthcare facilities:
• laboratory infrastructure can be overwhelmed due to refocusing on Covid-19 and not on HPV testing.
• cervical cancer screening may need to be isolated from other clinics/hospital infrastructure, as patients with cancer are more vulnerable to Covid-19 infection.
• Medical resources are overwhelmed and redirected as HPV testing and colposcopy have to be conducted by qualified professionals.
• HPV testing and colposcopy expose women and the healthcare professionals to a greater likelihood of Covid-19 infection as the examination increases doctor/patient interaction time than a TruScreen examination.

In contrast, TruScreen device:
• is portable and reduces the time for doctor/patient interaction, reducing the risk of Covid infection for women and healthcare professionals.
• does not burden the existing healthcare infrastructure and can be set up outside of hospital and clinical facilities.
• is easy to train on and does not require doctors to perform the examination.
• there is no handling and collection of tissue samples, reducing the infection risks and costs.
• is a valid method for screening of women who are HPV positive especially in regions where cytology and colposcopy are not readily available.

Researchers concluded that TruScreen cervical cancer screening system is a non-invasive screening method, that can be used to identify cervical lesions quickly and is especially suitable as a triage tool for HR-HPV-positive women facing Covid-19 (SARS-CoV-2) exposure and infection risks in the hospital setting.


Research Confirms TRU Device Suitable For Use In A COVID 19 Environment.PDF

1. The International Journal of Gynaecology and Obstetrics, Princess Nothemba Simelela; First published: 02 December 2020,
https://doi.org/10.1002/ijgo.13484 'WHO global strategy to eliminate cervical cancer as a public health problem: An opportunity
to make it a disease of the past'.
2. FUTURE ONCOLOGYVOL. 17, NO. 10, Ziyao Wang et al, https://www.futuremedicine.com/doi/10.2217/fon-2020-0928
'TruScreen detection of cervical tissues for high-risk human papillomavirus-infected women during the COVID-19 pandemic'.


TruScreen Limited published this content on 24 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2021 11:26:08 UTC.

© Publicnow 2021
07/08TRUSCREEN : Director Nominations Closing Date
07/01TRUSCREEN : First Sales Made in Eastern Europe
06/30TRUSCREEN : to Ship Cervical Cancer Screening Devices to Serbia in July
06/01TRUSCREEN : FY21 Preliminary Results
03/24TRUSCREEN : Research Confirms TruSreeen Suitability in COVID-19 Environment
03/23TRUSCREEN : Cervical Cancer Screening Device Suitable for COVID-19 Environment
03/01TRUSCREEN : Board Appointment
03/01TruScreen Group Limited Announces Board Changes
02/25TRUSCREEN : Executive Leadership Change
02/25TruScreen Group Limited Announces Executive Changes
More news
Sales 2021 1,97 M 1,38 M 1,38 M
Net income 2021 -3,49 M -2,43 M -2,43 M
Net cash 2021 5,26 M 3,66 M 3,66 M
P/E ratio 2021 -9,18x
Yield 2021 -
Capitalization 23,6 M 16,5 M 16,4 M
EV / Sales 2020 6,02x
EV / Sales 2021 15,5x
Nbr of Employees -
Free-Float 69,8%
Duration : Period :
TruScreen Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Mean consensus -
Number of Analysts
Last Close Price 0,07 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Juliet Hull Chief Executive Officer & Director
Guy Robertson Chief Financial Officer & Secretary
Peng Ho Non-Executive Chairman
Edmond Capcelea Chief Technology Officer
Nicole Melia Manager-Administration & Marketing
Sector and Competitors